Travere Therapeutics, Inc.
TVTX
$62.14
$0.711.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 6.21% | -1,459.55% | -89.38% | 301.54% | 69.06% |
| Total Depreciation and Amortization | -83.21% | 39.01% | 14.88% | 12.64% | 9.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 261.35% | 214.82% | -242.73% | 8.49% | -5.67% |
| Change in Net Operating Assets | 163.16% | -185.67% | 241.07% | -562.15% | 76.20% |
| Cash from Operations | 243.86% | -166.52% | 323.82% | 187.32% | 111.81% |
| Capital Expenditure | -- | -- | 367.86% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,057.29% | 120.48% | -221.31% | 1,688.27% | -88.25% |
| Cash from Investing | -1,057.29% | 120.55% | -221.07% | 1,685.38% | -88.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | 538.55% | -82.62% | 565.13% | 104.50% | -52.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,099.05% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash from Financing | 4,360.44% | -84.24% | 140.83% | -4,529.76% | -60.33% |
| Foreign Exchange rate Adjustments | 220.00% | 85.47% | -299.52% | -89.38% | 255.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 368.34% | 18.01% | -150.02% | 169.86% | 294.32% |